We are honored to announce the successful completion of enrollment in the OCT Sub-Study of TRANSFORM II, a landmark clinical trial evaluating Sirolimus-Coated Balloons (SCB) versus Drug-Eluting Stents (DES) in the treatment of native coronary artery disease. This global effort represents the highest standards of clinical excellence, driven by leading investigators across renowned institutions. We extend our sincere appreciation to these esteemed professionals for their unwavering dedication and invaluable contributions.
🔹 Dr. Carlos Campos – Instituto do Coração de São Paulo – FMUSP, Brazil🔹 Dr. Ricardo Costa– Instituto Dante Pazzanese de Cardiologia, Brazil🔹 Dr. Fernando Alfonso – Hospital de La Princesa, Madrid🔹 Dr. Maarten A. Vink – OLVG, Amsterdam🔹 Dr. Fazila Malik – National Heart Foundation, Bangladesh🔹 Prof. Bernardo Cortese, Study Chairman.
Led by the Fondazione Ricerca e Innovazione Cardiovascolare and DCB ACADEMY, the TRANSFORM II study continues to set new benchmarks in clinical excellence, coronary innovation, and global scientific leadership. Science in Action. Innovation in Care. Impact in Lives.
STRAT – CI 2025 | The first congress organized in Latin America dedicated to DCB